FDA approves first respiratory syncytial virus vaccine

The US Food and Drug Administration has approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the USA, achieving. an elusive quest that has been decades in the making.

Developed by UK pharma major GSK (LSE: GSK), Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Analysts have estimated the market for RSV vaccines to surpass $10 billion by 2030. Credit Suisse analysts expect $2.5 billion in peak sales for GSK's RSV vaccine for older adults. Later this month, the FDA is expected to make an approval decision on Pfizer’s competing RSV vaccine.